As of 2026-09-10, the EV/EBITDA ratio of Cue Biopharma Inc (CUE) is -0.95. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CUE's latest enterprise value is 178.19 mil USD. CUE's TTM EBITDA according to its financial statements is -187.29 mil USD. Dividing these 2 quantities gives us the above CUE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.7x - 16.5x | 16.0x |
| Forward P/E multiples | 17.4x - 20.4x | 19.0x |
| Fair Price | (504.93) - (480.39) | (508.43) |
| Upside | -1755.5% - -1675.1% | -1767.0% |
| Date | EV/EBITDA |
| 2026-09-09 | -0.95 |
| 2026-09-08 | -0.93 |
| 2026-09-04 | -0.85 |
| 2026-09-03 | -0.85 |
| 2026-09-02 | -0.83 |
| 2026-09-01 | -0.88 |
| 2026-08-31 | -0.78 |
| 2026-08-28 | -0.86 |
| 2026-08-27 | -0.87 |
| 2026-08-26 | -0.89 |
| 2026-08-25 | -0.82 |
| 2026-08-24 | -0.70 |
| 2026-08-21 | -0.73 |
| 2026-08-20 | -0.75 |
| 2026-08-19 | -0.81 |
| 2026-08-18 | -0.79 |
| 2026-08-17 | -0.85 |
| 2026-08-14 | -1.08 |
| 2026-08-13 | -0.97 |
| 2026-08-12 | -0.95 |
| 2026-08-11 | -0.87 |
| 2026-08-10 | -0.80 |
| 2026-08-07 | -0.84 |
| 2026-08-06 | -0.83 |
| 2026-08-05 | -0.82 |
| 2026-08-04 | -0.82 |
| 2026-08-03 | -0.83 |
| 2026-07-31 | -0.83 |
| 2026-07-30 | -0.95 |
| 2026-07-29 | -0.87 |
| 2026-07-28 | -0.94 |
| 2026-07-27 | -1.02 |
| 2026-07-24 | -1.01 |
| 2026-07-23 | -1.04 |
| 2026-07-22 | -1.08 |
| 2026-07-21 | -1.05 |
| 2026-07-20 | -0.97 |
| 2026-07-17 | -0.97 |
| 2026-07-16 | -0.86 |
| 2026-07-15 | -0.88 |
| 2026-07-14 | -0.98 |
| 2026-07-13 | -0.97 |
| 2026-07-10 | -1.17 |
| 2026-07-09 | -1.16 |
| 2026-07-08 | -1.12 |
| 2026-07-07 | -1.05 |
| 2026-07-06 | -1.02 |
| 2026-07-02 | -0.87 |
| 2026-07-01 | -0.88 |
| 2026-06-30 | -0.99 |